TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 12 Nov 2018 According to the InnoMedica media release, the Swissmedic has approved this trial. The Graubunden Cantonal Hospital was officially opened as the second study centre and recruitment is ongoing at this centre.
- 06 Sep 2018 Status changed from not yet recruiting to recruiting.
- 04 Jan 2018 New trial record